GlassScriptPhysician profile
Hayley Chatagnier
NPI 1609589597
$1,338.82
in general payments reported to CMS, 2019-2025
23 companies · $670 in 2025
The $670 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $215 · 2024: $454 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,338.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $264.91 | 2023-2025 | Azstarys |
| Genzyme Corporation | $227.11 | 2025 | |
| Dexcom, INC. | $195.00 | 2024-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $123.83 | 2023-2024 | Jornay Pm |
| Exact Sciences Corporation | $69.44 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $59.52 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Supernus Pharmaceuticals, INC. | $55.86 | 2024-2025 | Qelbree |
| Cranial Technologies, INC | $38.63 | 2024-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $33.46 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Collegium Pharmaceutical, INC. | $31.30 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $22.17 | 2024 | Auvelity |
| Pfizer INC. | $22.17 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.25 | 2023 | Trintellix |
| Phathom Pharmaceuticals, INC. | $19.65 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $19.25 | 2024 | Xarelto |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.10 | 2023 | |
| Phadia US INC. | $18.97 | 2024 | Immunocap |
| Cipher Pharmaceuticals US LLC | $18.28 | 2025 | Natroba, Spinosad |
| Sumitomo Pharma America, INC. | $17.21 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $16.44 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.86 | 2023 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $15.21 | 2023 | Rexulti |
| Lilly USA, LLC | $15.20 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hayley Chatagnier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.